Amyotrophic Lateral Sclerosis Market On Track For USD 1,271.6 Mn Revenue By 2033, Growing At 6.5% CAGR | Dimension Market Research

Advancements and Projections in the Amyotrophic Lateral Sclerosis Market: Insights, Trends, Opportunities, and Recent Developments

New York, May 28, 2024 (GLOBE NEWSWIRE) — Market Overview

The Global Amyotrophic Lateral Sclerosis Market size was valued at USD 673.4 million in 2023 and is further anticipated to reach USD 1,271.6 million by 2033 a CAGR of 6.5 % according to Dimension Market Research.

Amyotrophic lateral sclerosis (ALS) is a neurological condition affecting nerve cells in the brain and spinal cord, leading to paralysis due to the degeneration of motor neurons. ALS is characterized by the degeneration of the motor nervous system, with symptoms ranging from mild muscle weakness, nausea, and stiffness to rapid progression affecting daily activities such as breathing and swallowing.

Click to Request Sample Report and Drive Impactful Decisions:

This market is growing due to the increasing prevalence of ALS, leading to a higher demand for treatments as more individuals are diagnosed with these disorders. An increase in the incidence of ALS encourages researchers to focus on developing new medications, raising funds, and prioritizing efforts related to the condition.

Important Insights

  • The global amyotrophic lateral sclerosis market is expected to grow by USD 1,271.6 million by 2033 from 2025 with a CAGR of 6.5 %.
  • Sporadic amyotrophic lateral sclerosis is forecasted to lead the ALS market in 2024 based on type as it is the most common form of the disease, accounting for the majority of patients suffering from amyotrophic lateral sclerosis.
  • Medication plays a significant role in treating patients with amyotrophic lateral sclerosis (ALS), predicted to account for 53.7% of the market share in 2024as they are administered orally, topically, intravenously, or via other routes.
  • Based on distribution channels in the global ALS market, hospital pharmacies expected to dominate the largest share at 44.9% in 2024 as they are important in diagnosing, treating, and managing ALS.
  • North America is expected to dominate the amyotrophic lateral sclerosis market with a 41.5% share in 2024, due to the availability of recently developed immunosuppressants and the presence of a favorable reimbursement scenario in this region.

Latest Trends

  • Biomarkers are being researched in the ALS market as measurable disease indicators aiding in early diagnosis, patient classification, and treatment tracking.
  • Researchers focus on gene mutations, epigenetic factors, RNA metabolism, and protein aggregation to understand ALS pathogenesis complexities.
  • Patient-centered care is gaining importance in the ALS market, with an increase in patient care centers providing tailored, complex care to meet individual patient needs.

Competitive Landscape

  • Amyotrophic lateral sclerosis (ALS) market is highly competitive, featuring leading pharmaceutical firms, research institutions, and healthcare organizations which actively engaged in discovering and developing new ALS treatments.
  • Major players demonstrate significant success in advancing ALS diagnosis and research. Some of the major key players in the Global Amyotrophic Lateral Sclerosis Market are Mitsubishi Tanabe Pharma Corporation, Sun Pharmaceutical Industries Ltd., CORESTEM Inc., BrainStorm Cell Limited, Amylyx Pharmaceuticals Inc., AB Science, Ionis Pharmaceuticals, and many others.

Some of the prominent market players:

  • Mitsubishi Tanabe Pharma Corporation
  • Sun Pharmaceutical Industries Ltd.
  • BrainStorm Cell Limited
  • Amylyx Pharmaceuticals Inc.
  • AB Science
  • Ionis Pharmaceuticals
  • Biohaven Pharmaceutical
  • Biogen
  • CRISPR Therapeutics
  • AbbVie Inc.
  • Boehringer Ingelheim International GmbH
  • Other Key Players

Transform your business approach with strategic insights from our report. Get in touch to request our brochure today! :

Amyotrophic Lateral Sclerosis Market Scope

Report Highlights Details
Market Size (2023) USD 718.8 Mn
Forecast Value (2033) USD 1,271.6 Mn
CAGR (2024-2033) 6.5 %
North America Revenue Share 41.5%
Europe Revenue Share 28.1%
Historical Data 2017 – 2022
Forecast Data 2025 – 2033
Base Year 2023
Estimate Year 2024
Segments Covered By Type, By Treatment, By Distribution Channel
Regional Coverage North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA)

Market Analysis

Medication is expected to hold the largest market share of 53.7% and dominate the market based on treatment in 2024, due to it’s their essential role in mitigating this disease, which minimizes the suffering of the patient.

It also acts as a barrier in some rare cases where it slows down the disease progression. They are also a critical detail in the remedy of ALS as they offer the desire to enhance the quality of lifestyles and in all likelihood expand the survival fee of the patients.

Many fundamental pharmaceutical organizations and studies corporations are heavily investing in drug improvement for the remedy of ALS. This initiative’s attention to drug development has led to a huge variety of promising scientific trials, similarly emphasizing the significance of drugs inside the remedy of ALS.

Purchase the Competition Analysis Dashboard Today:

Amyotrophic lateral sclerosis Market Segmentation

By Type

  • Sporadic ALS
  • Familial ALS

By Treatment

  • Medication
  • Physical Therapy
  • Speech Therapy

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Growth Drivers

  • The growing number of amyotrophic lateral sclerosis (ALS) patients is a key factor driving market growth, leading to advancements in diagnostic techniques and increased detection rates.
  • The aging population affected by ALS and heightened awareness among healthcare professionals and patients are also contributing to the expansion of the global ALS market.
  • The rising demand for ALS treatments due to increased prevalence not only drives market growth but also spurs intensified research and development efforts.
  • The regulatory environment, including government criteria for drug approval and clinical trials, plays a crucial role in shaping the ALS market and ensuring treatment accessibility.


  • ALS is a neurological disease without a cure, leading to limited options for managing the disease, with current treatments focused on symptom relief and slowing disease progression which obstruct the growth of this market.
  • The absence of effective treatments not only limits patients’ choices but also reduces the demand for advancements in ALS therapies, thereby hindering market growth.
  • The high cost associated with ALS and its therapies, including medical devices, consultations, and supportive care, poses a significant concern, particularly for patients requiring ongoing and intensive care, thus impeding market expansion.

Growth Opportunities

  • The ALS market shows promising opportunities for the development of advanced therapies, with current research concentrating on gene therapy, stem cell therapy, and immunotherapy to offer personalized treatments for distinct patient subgroups.
  • Stem cell therapy is being explored for its regenerative potential in repairing damaged motor neurons, presenting a potential avenue for disease modification in ALS.
  • Digital health solutions like telehealth are enhancing care accessibility for ALS patients, especially those unable to visit specialized centers, while also improving data collection and analysis, potentially accelerating the advancement of new ALS therapies.

Regional Analysis

North America, is predicted to dominate the global amyotrophic lateral sclerosis market with 41.5 % of market shares in 2024 and is anticipated to show significant growth in the upcoming period. This region boasts a highly advanced healthcare landscape, including pharmaceutical companies, & top-tier medical and research institutions, fostering research into the early diagnosis and treatment of amyotrophic lateral sclerosis (ALS).

Thus, this region stands out as a focal point in the global ALS market. They play a leading role in ALS research due to its many ongoing clinical trials & state-of-the-art laboratories. Collaboration among researchers, institutions, & pharmaceutical firms is actively encouraged and facilitated in this region, enhancing its position in the global ALS market.

By Region

North America

  • The U.S.
  • Canada


  • Germany
  • The U.K.
  • France
  • Italy
  • Russia
  • Spain
  • Benelux
  • Nordic
  • Rest of Europe


  • China
  • Japan
  • South Korea
  • India
  • ANZ
  • Rest of Asia-Pacific

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of Latin America

Middle East & Africa

  • Saudi Arabia
  • UAE
  • South Africa
  • Israel
  • Egypt
  • Rest of MEA

Click to Request Sample Report and Drive Impactful Decisions:

Recent Developments in the Amyotrophic Lateral Sclerosis Market

  • January 2023: Amylyx Pharmaceuticals, Inc. revealed an exclusive license and distribution agreement with Neopharm, under which Neopharm will commercialize AMX0035 (sodium phenylbutyrate and ursodoxicoltaurine) upon regulatory approval for ALS treatment in Israel, Gaza, West Bank, and the Palestinian region.
  • September 2022: Amylyx Pharmaceuticals, Inc. shared the FDA’s approval of RELYVRIO (sodium phenylbutyrate and taurursodiol) for treating ALS in adults.
  • July 2022: Biogen Inc. (Nasdaq: BIIB) revealed that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for tofersen, an experimental medication designed for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS).
  • June 2022: Mitsubishi Tanabe Pharma America, Inc., a subsidiary of Mitsubishi Chemical Holdings Corporation, announced the availability of RADICAVA ORS (edaravone) in the United States for treating amyotrophic lateral sclerosis (ALS).
  • May 2022: Mitsubishi Tanabe Pharma America, Inc. announced FDA approval for RADICAVA ORS (edaravone) as an oral form for ALS treatment in the United States.

Browse More Related Reports

  • Antibiotics Market reached a value of USD 53.7 billion in 2023, and it is further anticipated to reach a market value of USD 89.2 billion by 2033 at a CAGR of 4.7%.
  • Ampicillin Market size is projected to reach a market value of USD 388.1 million by the end of 2024 which is further predicted to reach a value of USD 480.1 million by 2033 at a CAGR of 2.4%.
  • Dental Bone Graft Substitute Market is expected to reach a value of USD 886.4 million by the end of 2024, and it is further anticipated to reach a market value of USD 2,066.8 million by 2033 at a CAGR of 9.9%.
  • Protein Supplements Market size is anticipated to be valued at USD 7.2 million in 2024 and is further predicted to reach USD 14.7 million by 2033, at a CAGR of 8.3 %.
  • Insulin Delivery Devices Market is expected to dominate with USD 35.2 billion in 2024 and is anticipated to grow to USD 75.4 billion by 2033 at a CAGR of 8.8%
  • Nutraceuticals Market size is anticipated to be valued at USD 367.3 billion in 2024 and is further predicted to reach USD 863.7 billion by 2033, at a CAGR of 10.0 %.
  • Wheat Protein Market size is anticipated to be valued at USD 7.3 billion in 2024 and is further predicted to reach USD 10.7 billion by 2033, at a CAGR of 4.4 %.
  • Pharmacogenomics Market is estimated to reach a market size of USD 6.9 billion which is foreseen to be USD 12.0 billion in 2033 with a CAGR of 6.3%.
  • Anticipated that the U.S. Market for Acellular Dermal Matrices will reach a market value of 3.7 USD billion in 2024 and will surge higher to USD 9.8 billion by 2033 at a CAGR of 11.4% in the forecast period (2024 – 2033).
  • U.S. Central Venous Catheter Market is projected to reach a market value of USD 1,220.4 million in 2024 and is further expected to attain a market value of USD 2,140.1 million by 2033 at a CAGR of 6.4%.

About Dimension Market Research (DMR)

Dimension Market Research (DMR) is a market research and consulting firm based in India & US, with its headquarters located in the USA (New York). The company believes in providing the best and most valuable data to its customers using the best resources analysts into work, to create unmatchable insights into the industries, and markets while offering in-depth results of over 30 industries, and all major regions across the world.

We also believe that our clients don’t always want what they see, so we provide customized reports as well, as per their specific requirements to create the best possible outcomes for them and enhance their business through our data and insights in every possible way.

CONTACT: Global Business Development Team United States 957 Route 33, Suite 12 #308 Hamilton Square, NJ-08690 Phone No.: +1 732 369 9777, +91 88267 74855

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Privacy & Cookies Policy